**TO THE EDITOR:** We read the recent review by Fukui et al[@b1-jnm-25-332] in this journal. In their paper, they referred that the bacterial product short chain fatty acid promotes glucose regulating hormones including glucagon-like peptide 1.[@b1-jnm-25-332] We consider their review to be accurate and to provide further insight to the following phenomena.

Mizagliflozin, a novel sodium-glucose cotransporter 1 inhibitor, suppresses the absorption of glucose and water in the intestine.[@b2-jnm-25-332],[@b3-jnm-25-332] We reported that mizagliflozin showed favourable efficacy and safety for patients with functional constipation and the risk of hypoglycaemia would be low.[@b4-jnm-25-332] However, the dynamic data of postprandial plasma glucose under the administration of mizagliflozin has not been shown yet.

A randomised open-label study which evaluated the effects of oral administration of mizagliflozin 5 mg or 10 mg once daily at 30 minutes after breakfast for 2 weeks on plasma glucose and spontaneous bowel movement in patients with functional constipation was conducted in Japan ([ClinicalTrials.gov](http://ClinicalTrials.gov) NCT02343978). Twenty five patients (5 mg, n = 13 and 10 mg, n = 12) were enrolled in the study. After 2-weeks, postprandial plasma glucose and insulin at 1 hour and 2 hours in 10 mg of mizagliflozin and insulin at 2 hours in 5 mg of mizagliflozin were significantly lower than those in the baseline ([Table](#t1-jnm-25-332){ref-type="table"}). Areas under the curves for plasma glucose and insulin were not changed by 5 mg but significantly reduced by 10 mg of mizagliflozin (glucose, *P* = 0.043 and insulin, *P* = 0.007, one-sample *t* test). No hypoglycemic symptoms were induced by mizagliflozin but one patient showed hypoglycemic value (58 mg/dL) of postprandial plasma glucose at 2 hours in 10 mg of mizagliflozin. The mean number of spontaneous bowel movement per week significantly increased from 2.13 (SD, 0.45) at baseline to 7.99 (9.35) at week 2 in the 5 mg group and from 1.76 (0.62) to 6.81 (4.94) in the 10 mg group.

These results suggest that mizagliflozin actually inhibits postprandial glucose absorption from the intestine and has insulin-sparing effect. As Spiller[@b5-jnm-25-332] previously commented, altered microbiota by the luminal glucose is one of factors affecting the effect of mizagliflozin. Therefore, this study provides another evidence of the review by Fukui et al.[@b1-jnm-25-332] This study also supports the concept of low risk of hypoglycemia by sodium-glucose cotransporter 1 inhibitors[@b6-jnm-25-332], but low value of plasma glucose in rare cases should be recognized for further clinical studies.
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Changes in Plasma Glucose and Insulin Levels in the Meal Tolerance Test in the 5 mg and 10 mg Group

  Group                    Weeks   Item         Times (hr)   n    Mean    SD      Min    Q1     Median   Q3     Max     *P*-value (week 0 vs 2)
  ------------------------ ------- ------------ ------------ ---- ------- ------- ------ ------ -------- ------ ------- -------------------------
  Plasma glucose (mg/dL)                                                                                                
   Mizagliflozin 5 mg      0       FPG          0            13   94.2    11.1    79     87     92       100    114     \-
                                   PPG          0.5          13   141.8   18.7    111    133    141      151    175     \-
                                                1            13   139.2   41.9    88     104    131      165    219     \-
                                                2            13   105.0   36.4    72     86     90       108    208     \-
                           2       FPG          0            13   95.1    13.0    77     87     91       101    124     0.665
                                   PPG          0.5          13   140.3   32.0    109    116    135      156    210     0.797
                                                1            13   125.8   48.2    81     98     110      129    231     0.216
                                                2            13   91.0    20.3    71     78     87       89     134     0.064
   Mizagliflozin 10 mg     0       FPG          0            12   92.6    10.0    79     88     92       96     118     \-
                                   PPG          0.5          12   143.4   31.0    107    121    141      150    206     \-
                                                1            12   129.0   45.0    81     100    109      154    243     \-
                                                2            12   105.8   28.5    76     84     100      124    163     \-
                           2       FPG          0            12   93.4    7.2     83     89     93       97     111     0.659
                                   PPG          0.5          12   144.6   20.4    105    127    147      159    177     0.839
                                                1            12   110.0   26.8    72     92     98       132    156     0.044
                                                2            12   82.6    14.6    58     76     83       91     105     0.009
  Insulin (μU/mL)                                                                                                       
   Mizagliflozin 5 mg      0       Fasting      0            13   5.28    2.24    2.7    3.8    4.9      5.6    10.1    \-
                                   After meal   0.5          13   65.41   32.58   28.4   40.2   54.8     96.2   119.5   \-
                                                1            13   58.07   25.60   18.8   40.8   49.5     70.9   105.8   \-
                                                2            13   41.22   23.28   15.1   20.8   36.6     56.8   87.9    \-
                           2       Fasting      0            13   5.75    3.09    1.8    3.7    5.5      6.6    11.1    0·519
                                   After meal   0.5          13   68.16   31.28   22.7   46.6   63.9     89.0   121.3   0·504
                                                1            13   53.07   27.98   24.7   28.1   37.2     72.5   111.5   0·577
                                                2            13   13.62   8.16    4.5    7.0    10.6     19.6   32.6    \< 0.001
   Mizagliflozin 10 mg     0       Fasting      0            12   5.23    3.03    1.2    3.4    4.2      7.1    11.2    \-
                                   After meal   0.5          12   79.03   74.08   21.8   37.5   58.1     93.6   296.0   \-
                                                1            12   56.49   28.44   31.5   39.3   44.4     68.4   130.3   \-
                                                2            12   35.34   12.58   18.1   23.3   36.5     45.5   57.7    \-
                           2       Fasting      0            12   4.89    1.77    3.2    3.9    4.5      5.2    9.9     0.634
                                   After meal   0.5          12   72.98   50.39   32.2   39.2   55.4     77.7   190.7   0.582
                                                1            12   39.88   17.11   18.8   21.6   39.9     55.1   64.9    0.021
                                                2            12   8.92    2.85    5.0    6.7    8.0      12.0   13.5    \< 0.001

Min, minimum; Q, quartile; Max, maximum; FPG, fasting plasma glucose; PPG, postprandial plasma glucose.

At week 0 (without mizagliflozin) and 2 (with mizagliflozin), blood glucose and insulin levels were measured at 0, 30, 60, and 120 minutes after the patients ingested 431 kcal standard breakfast of 67.2 g to 68.5 g of carbohydrates, 5.4 g to 5.6 g of fat, and 19.7 g to 21.1 g of protein.

*P*-values were calculated using the one-sample *t* test.
